| language |
eng
|
| Author |
Sato Shuichi
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
Miyake Tatsuya
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
ISHIHARA, Shunji
Department of Internal Medicine II, Shimane University Faculty of Medicine
|
| Subject | nonalcoholic; steatohepatitis; type 2 diabetes mellitus; sodium-glucose; cotransporter 2-inhibitor; dapagliflozin; open-label
|
| Journal Title |
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
|
| Volume | 87
|
| Start Page | 13
|
| End Page | 19
|
| ISSN | 0011-393X
|
| ISSN（Online） | 1879-0313
|
| Published Date | 2017
|
| DOI | |
| PubMed ID | |
| Publisher | ELSEVIER SCIENCE INC
|
| NII Type |
Journal Article
|
| OAI-PMH Set |
Faculty of Medicine
|
| Remark | Dapagliflozin was developed by AstraZeneca, who provided funding for publication fees and development of the manuscript, but did not play any other role in the study design; collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. HT and YK have received honoraria from AstraZeneca K.K. Funding to pay for editorial support and the Open Access publication charges for this article were provided by AstraZeneca K.K. and Ono Pharmaceutical Co, Ltd. The authors have indicated that they have no other conflicts of interest regarding the content of this article.
|
